Clinical trialPhase 1Terminated
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer: A Phase I Study #108181
- Outcome
- Stopped earlyslow enrollment and lack of funding (Business decision)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- March 2007
- Expected end
- August 2008
- Enrollment
- 25 participants
- Sites
- 1
- Primary outcomes
- Overall Survival for Patients With Metastatic Pancreatic Cancer.
- Sponsor
- Other
- Results posted
- 2014-05-19
- Last update
- 8 March 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Phase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer.
Detailed description public domain (ClinicalTrials.gov)
To evaluate the safety/tolerability and potential antitumor activity of lapatinib, at dose ranges of 1000 to 1500 mg/d, in combination with gemcitabine and gemcitabine/oxaliplatin (GEMOX) in patients with advanced pancreaticobiliary cancer.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Overall Survival for Patients With Metastatic Pancreatic Cancer. [Date of study entry until the date of death, up to 12 months.]. Number, participants. Arm 1 (n=3): 3; Arm 2 (n=11): 10; Arm 3 (n=6): 6; Arm 4 (n=5): 5.